Critical limb ischaemia and the response to bone marrow-derived cell therapy according to tcPO2 measurement.
Fiche publication
Date publication
janvier 2017
Journal
VASA. Zeitschrift fur Gefasskrankheiten
Auteurs
Membres identifiés du Cancéropôle Est :
Pr NGUYEN Philippe
Tous les auteurs :
Maufus M, Antoinette Sevestre-Pietri M, Sessa C, Pignon B, Egelhofer H, Dupas S, Nguyen P, Genty C, Pernod G
Lien Pubmed
Résumé
Cell therapy is an emerging potential biotherapy for critical limb ischaemia (CLI) patients who are not eligible for revascularization. However, the findings on this technique's efficacy are inconsistent. Trials investigating this topic focused on the more severe CLI patients who were often beyond any therapy. Therefore, identifying those who may truly benefit from cell transplantation is now warranted. To this end, we studied the prognostic value of tcPO2 for major amputation after 1 year in patients treated with bone marrow-derived cells.
Référence
VASA. 2017 Jan;46(1):23-28